Qureight: Revolutionizing Drug Development with AI-Powered Data Curation

Qureight is an AI-powered platform designed to accelerate drug development by efficiently curating and analyzing complex healthcare data. The platform leverages cutting-edge AI and machine learning to extract meaningful insights from various data sources, including clinical trial images, physiological data, and biomarkers. This allows biopharma companies, contract research organizations, and hospitals to make faster, more informed decisions throughout the drug development lifecycle.

Key Features and Capabilities

• AI-Driven Data Analytics: Qureight's core functionality lies in its ability to process and analyze vast amounts of complex healthcare data. This includes advanced algorithms for image analysis (CT scans, etc.), AI-assisted workflows, and cloud-based central image reads.
• Real-World Data Integration: The platform integrates real-world data from global partner healthcare institutions, enriching its analytical capabilities and providing a more comprehensive view of disease progression.
• Collaborative Analysis: Qureight facilitates collaborative analysis, enabling seamless data sharing and joint problem-solving among researchers and stakeholders.
• Purpose-Built Technology: Developed by leading healthcare experts, the platform offers a zero-footprint medical imaging viewing system with annotation capabilities and cloud-based ML model execution. It also provides fast, efficient, and AI-guided central read image workflows for clinical trials and the ability to generate synthetic study arms.
• Quantitative Imaging Analysis: Qureight offers AI-powered quantitative imaging analysis of CT scans, enabling precise quantification of lung volumes, airways, pulmonary vessels, and fibrosis.

Focus Areas: Lung and Heart Disease

Qureight currently focuses on lung and heart diseases, a field significantly larger than oncology in terms of drug development time, diagnostic costs, and reimbursement spending. The platform addresses the complexities of various conditions, including:

• Interstitial Lung Diseases (ILDs): Qureight helps streamline the diagnosis, monitoring, and clinical trial development for ILDs, a group of over 200 diseases causing lung tissue scarring and damage.
• Pulmonary Hypertension (PH): The platform assists in monitoring and managing PH, a condition characterized by increased pressure in the heart/lung vascular circuit, often requiring invasive procedures for diagnosis.
• Lung Cancer: Qureight supports research and development efforts for lung cancer treatments, including the analysis of treatment side effects on surrounding lung tissue.

Testimonials

• Professor Maria Belvisi (AstraZeneca): "The collaboration with Qureight supports AstraZeneca’s aim to harness data and technology to push the boundaries of science and deliver life-changing medicines to patients. Qureight’s AI technology allows us to investigate outcomes in multiple respiratory diseases, create new endpoints and improve patient selection for clinical trials in diseases such as Idiopathic Pulmonary Fibrosis."
• Dr. Rohit Batta (Vicore Pharma AB): "Vicore’s work with Qureight has highlighted information from our data that we otherwise wouldn’t have had access to. Following this analysis, we now know which patients are most likely to improve with C21, and how. This insight will prove invaluable as we continue our work to provide a much-needed new IPF treatment."
• Katie Gilliam (Clario): "The Qureight team helped smooth the transition of data transfer by effectively and efficiently setting up all the necessary steps prior to the transfer (creating a storing data location, providing access, providing input on data organization, etc) and collectively working with Clario to resolve any questions in a timely manner."

Conclusion

Qureight is transforming drug development by providing a powerful, AI-driven platform for data curation and analysis. Its focus on lung and heart diseases, coupled with its advanced technology and collaborative approach, positions it as a key player in accelerating the discovery and approval of life-changing medications.